Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor NCT05653349 VAYHIT1 (CVAY736112301) Indication Phase Patients Primary Outcome Measures Arms 1L Immune Thrombocytopenia Phase 3 225 Time from randomization to treatment failure (TTF) 2023 priorities Innovation: Clinical trials Neuroscience Intervention Target Patients Arm 1: Experimental: lanalumab Lower dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 2: lanalumab Higher dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 3: Placebo Comparator administered intravenously with corticosteroids oral or parentally (if clinically justified) Adult patients with primary ITP Readout Milestone(s) 2025 Publication TBD 82 Investor Relations | Q4 2022 Results Oncology NCT05653219 VAYHIT2 (CVAY736Q12301) Indication 2L Immune Thrombocytopenia Phase 3 Appendix Abbreviations Other Time from randomization to treatment failure (TTF) Phase Patients 150 Primary Outcome Measures Arms Intervention Arm 1: Experimental: eltrombopag and ianalumab lower dose Arm 2: Experimental: eltrombopag and ianalumab higher dose Arm 3: eltrombopag and placebo Primary ITP patients who failed steroids Target Patients Readout Milestone(s) 2025 Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation